This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CYP2B6 · Western blot design guide
CYP2B6 Western Blot Planning Guide
Plan a CYP2B6 Western blot around the catalog-observed 56.3 kDa band, image-backed A00861-2 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
CYP2B6 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 56.3 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Liver | |
| Negative control | Adipose tissue |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 56.3 kDa |
| ⓘ | Localization | Endoplasmic reticulum membrane / Microsome membrane |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human |
Section 1
Real Curated CYP2B6 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Liver |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A00861-2 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected CYP2B6 Western Blot Band Size?
Use the product-observed 56.3 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 56.3 kDa | Matches the authoritative product WB observation. |
| 56.3 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected CYP2B6 appearancePlan around 56.3 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 56.3 kDa; use this as the primary experimental expectation. |
| Calculated mass | 56.3 kDa from UniProt P20813; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A00861-2. |
| Situation | Likely cause | Next action |
|---|---|---|
| 56.3 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing CYP2B6 band
A00861-2 · CYP2B6
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for CYP2B6 Western blot
🧪Use Liver as the first positive-control candidate and Adipose tissue as the HPA Not detected negative candidate.
Positive control: Liver (High)
Negative control: Adipose tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for CYP2B6
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Liver | Reported tissue cells | High | Protein (HPA) | HPA → |
| Small intestine | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Kidney | Reported tissue cells | Low | Protein (HPA) | HPA → |
| Duodenum | Reported tissue cells | Low | Protein (HPA) | HPA → |
Section 3
Advanced CYP2B6 Western Blot Tips
Deeper troubleshooting and optimisation questions for CYP2B6, answered from its protein features.
Which band should guide the blot?
Use 56.3 kDa, the observation attached to the authoritative A00861-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 56.3 kDa expectation.
Which positive control should I start with?
Start with Liver, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Adipose tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for CYP2B6 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A00861-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
CYP2B6 Western Blot Reagents
Human-reactive CYP2B6 Western blot reagents with authoritative product imagery.
Real WB data
Anti-Cytochrome P450 2B6/CYP2B6 Antibody Picoband®
Cat # A00861-2
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P20813
- Human Protein Atlas — CYP2B6
- A00861-2 product record
- PMC2410158 — CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes (British journal of cancer, 2004)
- PMC13304254 — Pharmacogenetic CYP2B6 variants affect steroid hormone metabolism in human breast cancer cells (British journal of clinical pharmacology, 2026)
- PMC10502999 — METTL3 exacerbates insulin resistance in hepatocytes by regulating m(6)A modification of cytochrome P450 2B6 (Nutrition & metabolism, 2023)
